Updates
Cures For Hair Loss 2023 - News Feed
A very good idea is to bookmark this article page in your browser or mobile browser for easy access on the latest hair loss cure and hair growth treatment news. This will allow you to check it easily for updates. If you are looking for a corresponding article from a past update, simply use the “Search” function on this site to locate the article. As always, thanks for reading and please share this information with all you feel would benefit from it!
Veradermics Doses First Patient With New Oral Hair Loss Drug
A fascinating new dermatology startup, Veradermics, announced today the dosing of its first patient in a phase 2 clinical trial for pattern hair loss. What makes this news especially exciting is that Veradermics' drug, for now referred to as VDPHL, is an oral medication. Further, it's a non-hormonal drug, which means it does not act on androgen hormones, such as DHT, like the drugs finasteride or dutasteride do. This means that users will likely not have to worry about sexual-related side effects. While information about VDPHL is limited at this time, Veradermics describes it as a "proprietary, non-hormonal oral treatment being developed for pattern hair loss." Stay tuned for further information about this drug program here on Follicle Thought.
HMI-115 Starts Phase 2 Clinical Trial In China
As the title says, HMI-115 is now at the phase 2 clinical trial stage in China. The placebo-controlled trial will include a 6 month treatment period for its participants. For now, this news seems to be the capstone of a quite active and positive year for hair loss treatment companies. To read the full story, check our last article on Hope Medicine.
OrganTech Takashi Kondo Interview
Follicle Thought was fortunate to receive exclusive information from OrganTech, the company developing Dr. Tsuji's hair cloning technology, this past week. An interview was conducted with OrganTech's CEO Takashi Kondo which shed light on the company's latest clinical trial projections, upcoming plans for funding, and more. Head to the Articles page, or use the Search bar on any page to read the full story.
JW Pharmaceutical Collaborates With Microneedle Technology Company
JW Pharmaceutical of Korea, a biotech company developing an extremely interesting Wnt targeting drug for hair regrowth, has announced a business collaboration with Theraject Asia. Under the agreement, JW Pharmaceutical and Theraject Asia will develop a microneedle-based hair regrowth treatment, according to Korean press. JW's drug candidate JW0061 will likely be the active pharmaceutical ingredient in the treatment. Microneedle treatments are essentially adhesive patches containing numerous needles of an extremely fine width, which deliver API's into the bloodstream or scalp. They are thought to be next-generation drug delivery technologies and are still in early stage development for practical clinical use.
Triple Hair’s TH-07 Licensed By South Korean Pharma Co.
Triple Hair of Canada announced yesterday that their flagship drug candidate TH-07 has been licensed by Mother's Pharmaceutical of Korea. TH-07 is a combinatorial topical pharmaceutical product for hair regrowth comprising minoxidil, finasteride, and latanoprost. With the hair growth capability of those three ingredients well documented (especially with minoxidil and finasteride), the product stands to be a logical, albeit familiar, prescription treatment success. For the North American markets, TH-07 is still preparing to enter a pivotal phase 3 clinical trial, and the company's website is currently recruiting male patients.
The recent licensing agreement with Mother's Pharmaceutical appears to have given Triple Hair ~$2.75M in an up-front payment, with potential milestone payments as part of the deal. This capital will likely be put towards the initiation of a phase 3 clinical trial in North America to seek widespread regulatory approval as a safe and effective treatment for hair loss.
Inmagene Starts Phase 2 Alopecia Areata Trial
The alopecia areata pipeline continues to expand with companies reaching the clinical trial stage; an overall good sign for hair-related diseases. This time, Inmagene Biopharmaceuticals has entered a phase 2a clinical trial for its antibody candidate IMG-007 in adults with moderate to severe alopecia areata. IMG-007 is a monoclonal antibody therapy against the 0x40 protein, and is it also happens to be in trials against atopic dermatitis.
IMG-007's alopecia areata trial participants will be dosed intravenously over the course of 6 months, and the study will be open label, meaning there is no placebo involved. More information about the trial, which is recruiting in October 2023, can be found on its official clinical trial listing.
TrichoSeeds Co. & Fukuda Clinical Trial Start Update
Junji Fukuda PhD's hair cloning startup company, TrichoSeeds Co., is making news in the Japanese biotech sector these days. TrichoSeeds Co. has been selected as a finalist at the upcoming 5th Healthcare Venture Award event sponsored by the Japan Anti-Aging Association. Out of a pool of 34 candidates, TrichoSeeds was selected to the panel of 7 finalists competing for a grand prize of 1 million yen. In the company description of TrichoSeeds Co. on the Healthcare Venture Award website, which would naturally be provided by the company themselves, there is an update mentioned about the timeline for the start of TrichoSeeds' first hair cloning trial. Head to the Articles page to read more of the details shared about this important clinical trial.
Alopecia Areata Pipeline Expands With Horizon Therapeutics’ Bempikibart
Horizon Therapeutics is a global pharmaceutical company with multiple candidates for alopecia areata in its portfolio. On September 13, 2023, Horizon announced that, in conjunction with its partner Q32 Bio, it had initiated a phase 2 clinical trial for bempikibart in adults with severe alopecia areata. Bempikibart (formerly known as ADX-914) is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP.
In addition, Horizon Therapeutics also has another drug candidate, daxdilimab, currently being trialed for AA at phase 2.
Epibiotech Interview EPI-001 Clinical Trial In 2023
Follicle Thought published today a new interview with Epibiotech CEO Dr. Jong-Hyuk Sung. The topics covered include EPI-001 beginning its important phase 1 clinical trial in Korea, the Epibiotech pipeline, and alopecia areata therapies. Head to the Articles page, or if you are reading this long after its publication, search for "Epibiotech EPI-001 clinical trial" on this website to find the article.
Coegin Pharma To Develop Follicum’s FOL005 As Cosmetic
Coegin Pharma, the company which acquired Follicum several years ago, has new plans for the FOL005 peptide. After recently attempting to resurrect FOL005 from the clinical trials archive, the company has an even more ambitious plan for the compound - to market it as a cosmetic. This news was shared on Coegin's website in August 2023. Apparently, discussions with industry partners helped sway Coegin's interests towards a cosmetic development route. The potential upsides are a much faster development track which would mean consumers get the treatment faster and the company generates revenue sooner. Below is a slide from Follicum's latest presentation.
If you had not previously seen it, Follicum also shared a new presentation with the Follicle Thought audience in May 2023.